ENSCW
Leisure Acquisition Corp.
Price Chart
No historical data available
Latest Quote
$0.02
-0.00 (-7.41%)
Current Price
| Previous Close | $0.02 |
| Open | $0.02 |
| Day High | $0.02 |
| Day Low | $0.02 |
| Volume | 42,199 |
Stock Information
| Total Debt | $246K |
| Cash Equivalents | $745K |
| Revenue | $4.71M |
| Net Income | $-11.79M |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Sales | $4.71M |
| Income | $-11.79M |
| Book/sh | $-0.04 |
| Employees | 8 |
Financial Ratios
| Quick Ratio | 0.26 |
| Current Ratio | 0.71 |
Returns & Margins
| ROA | -218.22% |
| ROE | -1149.11% |
| Gross Margin | -120.42% |
| Operating Margin | -370.68% |
| Profit Margin | -250.36% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | -0.54 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 14.68M |
Performance History
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About Leisure Acquisition Corp.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,290,444 | $353,945 | $109,525 | $1,295,307 |
| Total Expenses | $6,730,134 | $10,718,187 | $24,222,095 | $19,870,431 |
| Other Income Expense | $33,569 | $445,857 | $4,999,046 | $-4,194,602 |
| Other Non Operating Income Expenses | $33,569 | $445,857 | $4,999,046 | $-1,874,856 |
| Net Non Operating Interest Income Expense | $-1,290,444 | $-353,945 | $-4,984,636 | $-5,080,868 |
| Interest Expense Non Operating | $1,290,444 | $353,945 | $109,525 | $1,295,307 |
| Operating Expense | $6,730,134 | $10,718,187 | $24,222,095 | $19,870,431 |
| Other Operating Expenses | $-5,210,031 | $-2,230,520 | $-2,523,383 | $-3,531,199 |
| General And Administrative Expense | $4,720,728 | $5,361,234 | $6,909,603 | $18,711,548 |
| Total Other Finance Cost | - | - | $4,875,111 | $3,785,561 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,986,935 | $-10,613,074 | $-24,172,292 | $-29,083,711 |
| Net Interest Income | $-1,290,444 | $-353,945 | $-4,984,636 | $-5,080,868 |
| Normalized Income | $-7,986,935 | $-10,613,074 | $-24,172,292 | $-26,763,965 |
| Net Income From Continuing And Discontinued Operation | $-7,986,935 | $-10,613,074 | $-24,172,292 | $-29,083,711 |
| Total Operating Income As Reported | $-6,730,134 | $-10,718,187 | $-24,222,095 | $-19,870,431 |
| Net Income Common Stockholders | $-7,987,225 | $-10,626,011 | $-25,085,496 | $-29,886,851 |
| Net Income | $-7,986,935 | $-10,613,074 | $-24,172,292 | $-29,083,711 |
| Net Income Including Noncontrolling Interests | $-7,987,009 | $-10,626,275 | $-24,207,685 | $-29,145,901 |
| Net Income Continuous Operations | $-7,987,009 | $-10,626,275 | $-24,207,685 | $-29,145,901 |
| Pretax Income | $-7,987,009 | $-10,626,275 | $-24,207,685 | $-29,145,901 |
| Operating Income | $-6,730,134 | $-10,718,187 | $-24,222,095 | $-19,870,431 |
| Special Income Charges | - | $146,479 | $1,792,154 | $-154,391 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,696,565 | $-10,272,330 | $-24,098,160 | $-25,530,697 |
| EBITDA (Bullshit earnings) | $-6,696,565 | $-10,272,330 | $-24,098,160 | $-27,850,443 |
| EBIT | $-6,696,565 | $-10,272,330 | $-24,098,160 | $-27,850,594 |
| Diluted NI Availto Com Stockholders | $-7,987,225 | $-10,626,011 | $-25,085,496 | $-29,886,851 |
| Otherunder Preferred Stock Dividend | $290 | $12,937 | $913,204 | $803,140 |
| Minority Interests | $74 | $13,201 | $35,393 | $62,190 |
| Research And Development | $7,219,437 | $7,587,473 | $19,835,875 | $4,690,082 |
| Selling General And Administration | $4,720,728 | $5,361,234 | $6,909,603 | $18,711,548 |
| Other Gand A | $4,720,728 | $5,361,234 | $6,909,603 | $18,711,548 |
| Total Unusual Items | - | $430,437 | $5,756,787 | $-2,319,746 |
| Total Unusual Items Excluding Goodwill | - | $430,437 | $5,756,787 | $-2,319,746 |
| Other Special Charges | - | $-146,479 | $-1,792,154 | $154,391 |
| Gain On Sale Of Security | - | $283,958 | $5,756,787 | $-2,319,746 |
| Reconciled Depreciation | - | - | $0 | $151 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,708,422 | $-322,858 | $-3,714,444 | $-7,878,243 |
| Total Assets | $5,597,232 | $2,708,085 | $5,885,052 | $16,417,349 |
| Total Non Current Assets | $252,550 | $419,217 | $585,883 | $754,756 |
| Other Non Current Assets | $252,550 | $419,217 | $585,883 | $754,756 |
| Current Assets | $5,344,682 | $2,288,868 | $5,299,169 | $15,662,593 |
| Other Current Assets | $18,000 | $18,000 | $27,165 | $24,721 |
| Prepaid Assets | $1,700,490 | $1,049,703 | $1,847,481 | $2,931,415 |
| Receivables | $124,115 | $97,561 | $276,821 | $441,721 |
| Other Receivables | $124,115 | $97,561 | $276,821 | $441,721 |
| Cash Cash Equivalents And Short Term Investments | $3,502,077 | $1,123,604 | $3,147,702 | $12,264,736 |
| Cash And Cash Equivalents | $3,502,077 | $1,123,604 | $3,147,702 | $12,264,736 |
| Debt | ||||
| Total Debt | $301,660 | $854,697 | $4,434,073 | $17,213,980 |
| Current Debt And Capital Lease Obligation | $301,660 | $854,697 | $4,293,925 | $12,773,029 |
| Current Debt | $301,660 | $854,697 | $4,266,610 | $12,748,155 |
| Other Current Borrowings | $301,660 | $854,697 | $4,266,610 | $12,748,155 |
| Net Debt | - | - | $1,259,056 | $4,924,370 |
| Long Term Debt And Capital Lease Obligation | - | - | $140,148 | $4,440,951 |
| Long Term Debt | - | - | $140,148 | $4,440,951 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,217,293 | $3,359,352 | $9,914,704 | $24,575,407 |
| Total Non Current Liabilities Net Minority Interest | $10,096 | $26,388 | $450,494 | $8,093,741 |
| Derivative Product Liabilities | $10,096 | $26,388 | $310,346 | $3,303,588 |
| Current Liabilities | $2,207,197 | $3,332,964 | $9,464,210 | $16,481,666 |
| Payables And Accrued Expenses | $1,905,537 | $2,478,267 | $5,170,285 | $3,708,637 |
| Payables | $1,357,079 | $1,936,007 | $2,943,791 | $301,104 |
| Accounts Payable | $1,357,079 | $1,936,007 | $2,943,791 | $301,104 |
| Other Non Current Liabilities | - | - | - | $349,202 |
| Current Deferred Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $3,708,422 | $-322,858 | $-3,714,444 | $-7,878,243 |
| Total Equity Gross Minority Interest | $3,379,939 | $-651,267 | $-4,029,652 | $-8,158,058 |
| Stockholders Equity | $3,708,422 | $-322,858 | $-3,714,444 | $-7,878,243 |
| Retained Earnings | $-129,544,299 | $-121,557,074 | $-110,931,063 | $-85,845,567 |
| Other | ||||
| Treasury Shares Number | $6 | $5 | - | - |
| Ordinary Shares Number | $1,355,773 | $209,738 | $35,633 | $6,845 |
| Share Issued | $1,355,779 | $209,743 | $35,633 | $6,845 |
| Tangible Book Value | $3,708,422 | $-322,858 | $-3,714,444 | $-7,878,243 |
| Invested Capital | $4,010,082 | $531,839 | $692,314 | $9,310,863 |
| Working Capital | $3,137,485 | $-1,044,096 | $-4,165,041 | $-819,073 |
| Total Capitalization | $3,708,422 | $-322,858 | $-3,574,296 | $-3,437,292 |
| Minority Interest | $-328,483 | $-328,409 | $-315,208 | $-279,815 |
| Additional Paid In Capital | $133,252,585 | $121,234,195 | $107,216,566 | $77,967,200 |
| Capital Stock | $136 | $21 | $53 | $124 |
| Common Stock | $136 | $21 | $53 | $124 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Accrued Expenses | $548,458 | $542,260 | $2,226,494 | $3,407,533 |
| Capital Lease Obligations | - | $0 | $27,315 | $24,874 |
| Current Capital Lease Obligation | - | $0 | $27,315 | $24,874 |
| Net PPE | - | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | $0 | $1,342,479 |
| Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-7,502,700 | $-10,779,982 | $-17,887,439 | $-8,242,177 |
| Operating Activities | ||||
| Operating Cash Flow | $-7,502,700 | $-10,779,982 | $-17,887,439 | $-8,242,177 |
| Cash Flow From Continuing Operating Activities | $-7,502,700 | $-10,779,982 | $-17,887,439 | $-8,242,177 |
| Operating Gains Losses | $-16,292 | $-283,958 | $-6,735,113 | $14,754,294 |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $4,500 | $0 |
| Cash Flow From Continuing Investing Activities | - | $0 | $4,500 | $0 |
| Net Other Investing Changes | - | - | $4,500 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $1,670,001 | $9,050,004 | $3,783,240 | $6,626,312 |
| Financing Cash Flow | $9,881,173 | $8,755,884 | $8,765,905 | $20,312,699 |
| Cash Flow From Continuing Financing Activities | $9,881,173 | $8,755,884 | $8,765,905 | $20,312,699 |
| Net Other Financing Charges | $-1,840,660 | $-899,547 | $-1,142,886 | $-488,543 |
| Net Common Stock Issuance | $1,670,001 | $9,050,004 | $3,783,240 | $6,626,312 |
| Common Stock Issuance | $1,670,001 | $9,050,004 | $3,783,240 | $6,626,312 |
| Other | ||||
| Repayment Of Debt | $-485,190 | $-1,000,208 | $-1,408,364 | $-467,774 |
| Issuance Of Debt | $0 | $1,605,635 | $7,533,915 | $14,379,842 |
| Income Tax Paid Supplemental Data | $3,200 | $3,200 | $1,600 | $1,600 |
| End Cash Position | $3,502,077 | $1,123,604 | $3,147,702 | $12,264,736 |
| Beginning Cash Position | $1,123,604 | $3,147,702 | $12,264,736 | $194,214 |
| Changes In Cash | $2,378,473 | $-2,024,098 | $-9,117,034 | $12,070,522 |
| Proceeds From Stock Option Exercised | $10,537,022 | $0 | $0 | $262,862 |
| Net Issuance Payments Of Debt | $-485,190 | $605,427 | $6,125,551 | $13,912,068 |
| Net Long Term Debt Issuance | $-485,190 | $605,427 | $6,125,551 | $13,912,068 |
| Long Term Debt Payments | $-485,190 | $-1,000,208 | $-1,408,364 | $-467,774 |
| Long Term Debt Issuance | $0 | $1,605,635 | $7,533,915 | $14,379,842 |
| Change In Working Capital | $-851,249 | $-947,079 | $5,481,820 | $-1,303,492 |
| Change In Payables And Accrued Expense | $-572,730 | $-2,518,520 | $3,664,164 | $754,248 |
| Change In Accrued Expense | $6,198 | $-1,284,233 | $1,021,478 | $2,177,742 |
| Change In Payable | $-578,928 | $-1,234,287 | $2,642,686 | $-1,423,494 |
| Change In Account Payable | $-578,928 | $-1,234,287 | $2,642,686 | $-1,423,494 |
| Change In Prepaid Assets | $-251,965 | $1,392,181 | $1,652,756 | $-1,616,019 |
| Change In Receivables | $-26,554 | $179,260 | $164,900 | $-441,721 |
| Other Non Cash Items | $1,241,127 | $344,649 | $8,293,850 | $7,331,007 |
| Stock Based Compensation | $110,723 | $879,160 | $1,071,843 | $121,764 |
| Unrealized Gain Loss On Investment Securities | $0 | $-146,479 | $-1,792,154 | - |
| Gain Loss On Investment Securities | $-16,292 | $-283,958 | $-6,730,613 | $14,252,337 |
| Net Income From Continuing Operations | $-7,987,009 | $-10,626,275 | $-24,207,685 | $-29,145,901 |
| Depreciation Amortization Depletion | - | - | $0 | $151 |
| Depreciation And Amortization | - | - | $0 | $151 |
| Depreciation | - | - | $0 | $151 |
Fetched: 2026-02-02